The overall ratings of 9 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Taro Pharmaceutical Industries Ltd. (TARO) drops from a C to a D rating. Taro Pharmaceutical Industries Ltd. is engaged in developing, manufacturing, and marketing prescription and over-the-counter pharmaceutical products, as well as active pharmaceutical ingredients in the United States, Canada and Israel. For more information, get Portfolio Grader’s complete analysis of TARO stock.

Medicines Company (MDCO) is having a tough week. The company’s rating falls from a B to a D. Medicines Company develops products that improve specialized care. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MDCO stock.

This is a rough week for Lannett Company, Inc. (LCI). The company’s rating falls to D from the previous week’s C. Lannett Company, Inc. manufactures and distributes pharmaceutical products under its own trade name and under generic names. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of LCI stock.

Flamel Technologies SA Sponsored ADR (FLML) earns a F this week, moving down from last week’s grade of D. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of FLML stock.

Innoviva, Inc. (INVA) experiences a ratings drop this week, going from last week’s C to a D. For more information, get Portfolio Grader’s complete analysis of INVA stock.

Slipping from a C to a D rating, Collegium Pharmaceutical, Inc. (COLL) takes a hit this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of COLL stock.

Zogenix, Inc. (ZGNX) gets weaker ratings this week as last week’s D drops to a F. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZGNX stock.

Juniper Pharmaceuticals, Inc. (JNP) slips from a D to a F this week. The company also gets F’s in operating margin growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of JNP stock.

Lipocine, Inc.’s (LPCN) rating weakens this week, dropping to a F versus last week’s D. Lipocine, Inc. is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.